全球制药巨头诺华和礼来近日宣布与Alphabet（谷歌母公司）旗下的AI制药企业Isomorphic Labs达成战略合作，价值高达30亿美元。这一合作主要关注小分子药物研发，重点为多靶点治疗。
这次合作的重点是利用AI技术进行药物研发，这可能改变传统药物研发的时间和成本。Isomorphic Labs表示，这些合作可能为公司带来近30亿美元的价值，不包括未来药物销售可能产生的特许权使用费。
诺华和礼来都是全球知名的制药公司，他们在药品研发和生产方面有着丰富的经验。而Isomorphic Labs作为Alphabet旗下的AI制药企业，其在AI技术方面的优势将为药物研发带来新的突破。
这次合作展示了AI技术在药物研发领域的巨大潜力。未来，随着AI技术的不断发展，我们有理由相信，药物研发将更加高效、准确，从而为患者带来更好的治疗效果。
英文标题：Novartis and Lilly in $3B Collaboration with AI Pharma Firm
英文关键词：Novartis, Lilly, AI Pharma
News content:
Global pharmaceutical giants Novartis and Lilly have recently announced a strategic collaboration with Isomorphic Labs, an AI制药 enterprise under Alphabet (the parent company of Google), worth up to $3 billion. This collaboration focuses on the research and development of small molecule drugs, with a emphasis on multi-target treatments.
The highlight of this collaboration is the use of AI technology for drug development, which may change the time and cost of traditional drug development. Isomorphic Labs stated that these collaborations may bring the company nearly $3 billion in value, not including potential royalties from future drug sales.
Novartis and Lilly are both well-known global pharmaceutical companies with rich experience in drug research, development, and production. Isomorphic Labs, as an AI pharmaceutical enterprise under Alphabet, has a competitive advantage in AI technology, which will bring breakthroughs in drug research and development.
This collaboration showcases the immense potential of AI technology in the field of drug development. In the future, with the continuous development of AI technology, we have reason to believe that drug development will become more efficient and accurate, thereby bringing better treatment effects to patients.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 1